60
Participants
Start Date
December 23, 2020
Primary Completion Date
December 31, 2028
Study Completion Date
December 31, 2032
Venetoclax/Acalabrutinib
All patients will receive a lead-in with 2 cycles of acalabrutinib 100 mg bid. Hereafter patients will continue with ramp-up of venetoclax followed by daily 400 mg venetoclax in combination with acalabrutinib for 24 cycles. Patients will be treated until they have received a total of 26 cycles or until progression, whichever comes first.
NOT_YET_RECRUITING
BE-Bruxelles-STLUC, Brussels
NOT_YET_RECRUITING
BE-Leuven-UZLEUVEN, Leuven
NOT_YET_RECRUITING
DK-Aarhus N-AUH, Aarhus
RECRUITING
NL-Den Bosch-JBZ, 's-Hertogenbosch
RECRUITING
NL-Amsterdam-AMC, Amsterdam
RECRUITING
NL-Arnhem-RIJNSTATE, Arnhem
RECRUITING
NL-Breda-AMPHIA, Breda
RECRUITING
NL-Delft-RDGG, Delft
NOT_YET_RECRUITING
NL-Dordrecht-ASZ, Dordrecht
RECRUITING
NL-Ede-ZGV, Ede
RECRUITING
NL-Eindhoven-MAXIMAMC, Eindhoven
RECRUITING
NL-Groningen-UMCG, Groningen
RECRUITING
NL-Leeuwarden-MCL, Leeuwarden
RECRUITING
NL-Maastricht-MUMC, Maastricht
RECRUITING
NL-Nieuwegein-ANTONIUS, Nieuwegein
RECRUITING
NL-Rotterdam-IKAZIA, Rotterdam
RECRUITING
NL-Rotterdam-MAASSTADZIEKENHUIS, Rotterdam
NOT_YET_RECRUITING
NL-Utrecht-UMCUTRECHT, Utrecht
Stichting Hemato-Oncologie voor Volwassenen Nederland
OTHER